**Supplemental Digital Content 2 – Table 2***.* Virologic and immunologic responses at 6, 12, and 24 months after initation of cART for 2157 HIV-infected individuals

|  |  |  |  |
| --- | --- | --- | --- |
|  | AHOD, n=1036 | TAHOD, n=1121 | All patients, n=2157 |
| 6 months’ responses |  |  |  |
| VR+IR+ | 624 (69%) | 463 (66%) | 1087 (68%) |
| VR+IR- | 84 (9%) | 162 (23%) | 246 (15%) |
| VR-IR+ | 150 (17%) | 45 (7%) | 195 (12%) |
| VR-IR- | 48 (5%) | 29 (4%) | 77 (5%) |
| Viral load or CD4 not available | 130 | 422 | 552 |
| 12 months’ responses |  |  |  |
| VR+IR+ | 585 (63%) | 465 (64%) | 1050 (63%) |
| VR+IR- | 118 (13%) | 193 (26%) | 311 (19%) |
| VR-IR+ | 169 (18%) | 37 (5%) | 206 (12%) |
| VR-IR- | 60 (6%) | 40 (5%) | 100 (6%) |
| Viral load or CD4 not available | 104 | 386 | 490 |
| 24 months’ responses |  |  |  |
| VR+IR+ | 705 (68%) | 808 (72%) | 1513 (70%) |
| VR+IR- | 69 (7%) | 209 (19%) | 278 (13%) |
| VR-IR+ | 188 (18%) | 51 (4%) | 239 (11%) |
| VR-IR- | 74 (7%) | 53 (5%) | 127 (6%) |

Data are frequencies and within cohort region percentages in parentheses. cART; combination antiretroviral treatment, VR; virologic response, IR;immunologic response, CD4; CD4 T-cell count